Last reviewed · How we verify

HSK39004 inhalation suspension

Haisco Pharmaceutical Group Co., Ltd. · Phase 2 active Small molecule

HSK39004 inhalation suspension is a Small molecule drug developed by Haisco Pharmaceutical Group Co., Ltd.. It is currently in Phase 2 development. Also known as: Ohtuvayre inhalation suspension.

At a glance

Generic nameHSK39004 inhalation suspension
Also known asOhtuvayre inhalation suspension
SponsorHaisco Pharmaceutical Group Co., Ltd.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HSK39004 inhalation suspension

What is HSK39004 inhalation suspension?

HSK39004 inhalation suspension is a Small molecule drug developed by Haisco Pharmaceutical Group Co., Ltd..

Who makes HSK39004 inhalation suspension?

HSK39004 inhalation suspension is developed by Haisco Pharmaceutical Group Co., Ltd. (see full Haisco Pharmaceutical Group Co., Ltd. pipeline at /company/haisco-pharmaceutical-group-co-ltd).

Is HSK39004 inhalation suspension also known as anything else?

HSK39004 inhalation suspension is also known as Ohtuvayre inhalation suspension.

What development phase is HSK39004 inhalation suspension in?

HSK39004 inhalation suspension is in Phase 2.

Related